Avity Investment Management Inc. Takes Position in Boston Scientific Corporation $BSX

Avity Investment Management Inc. purchased a new position in Boston Scientific Corporation (NYSE:BSX) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 162,526 shares of the medical equipment provider’s stock, valued at approximately $15,867,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of BSX. Danica Pension Livsforsikringsaktieselskab acquired a new position in shares of Boston Scientific in the 3rd quarter valued at approximately $173,673,000. Danske Bank A S acquired a new stake in shares of Boston Scientific during the 3rd quarter worth approximately $94,514,000. Caitong International Asset Management Co. Ltd bought a new position in Boston Scientific in the third quarter valued at approximately $404,000. Stance Capital LLC increased its stake in Boston Scientific by 613.5% in the third quarter. Stance Capital LLC now owns 21,998 shares of the medical equipment provider’s stock valued at $2,148,000 after acquiring an additional 18,915 shares during the last quarter. Finally, GM Advisory Group LLC raised its position in Boston Scientific by 77.2% during the third quarter. GM Advisory Group LLC now owns 3,700 shares of the medical equipment provider’s stock valued at $361,000 after purchasing an additional 1,612 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

BSX has been the subject of several recent analyst reports. TD Cowen cut their target price on Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Robert W. Baird lowered their price target on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Oppenheimer dropped their price objective on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research report on Friday, January 16th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $112.00 price objective on shares of Boston Scientific in a research note on Friday, February 6th. Finally, Evercore lowered their target price on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Boston Scientific currently has an average rating of “Buy” and an average price target of $107.32.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analyst support remains, with UBS keeping a “buy” rating despite trimming its price target — this preserves broker confidence and highlights upside vs. current levels. Benzinga
• Positive Sentiment: Market writeups note the pullback may be overdone given solid recent financials (quarterly revenue and EPS strength and guidance), which supports a rebound narrative among value- and momentum-seeking investors. Is Boston Scientific Corp. (BSX) Pull Back Overdone as Financial Results Impress?
• Positive Sentiment: News summaries explaining why BSX outpaced the market today help attract short-term flows and algos reacting to momentum and analyst notes. Why Boston Scientific (BSX) Outpaced the Stock Market Today
• Neutral Sentiment: Some investor notices and law-firm solicitations are informational and can amplify trading volume even if they don’t change fundamentals immediately; these items tend to keep the stock volatile near-term. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: Multiple securities class-action filings and numerous law‑firm lead‑plaintiff solicitations allege disclosure problems around the U.S. Electrophysiology unit; this raises potential litigation risk, settlement exposure and near-term headline risk that can weigh on valuation. Boston Scientific Lawsuits Put Electrophysiology Outlook And Valuation In Focus
• Negative Sentiment: Numerous law firms (Rosen, Pomerantz, Faruqi, Bernstein Liebhard, Robbins Geller, etc.) have issued alerts about the May 4 lead-plaintiff deadline — repetitive alerts keep legal risk top of mind for investors and can suppress sentiment until the cases are resolved or dismissed. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors…

Boston Scientific Stock Up 2.0%

NYSE:BSX opened at $71.19 on Wednesday. The firm’s 50 day simple moving average is $81.42 and its 200 day simple moving average is $92.71. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. Boston Scientific Corporation has a one year low of $67.56 and a one year high of $109.50. The company has a market cap of $105.64 billion, a PE ratio of 36.70, a P/E/G ratio of 0.98 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company’s revenue was up 15.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.50% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.